The immunotherapeutic human papillomavirus (HPV) vaccine tipapkinogen sovacivec (TS) provided complete histologic resolution of cervical intraepithelial neoplasia (CIN) grade 2/3, offering a potential nonsurgical option for cervical precancerous lesions which could stretch to other HPV-associated precursors or cancers in the future, a new study shows.
Use of antiepileptic drugs (AEDs) during pregnancy was significantly associated with an increased risk of language delay in offspring at 5 and 8 years of age, according to a study presented at EAN 2019.
Oral solithromycin may not be a suitable substitute for ceftriaxone plus azithromycin in the first-line treatment of uncomplicated genital gonorrhoea, according to results of the phase III SOLITAIRE-U* trial.
Delaying the transfer of embryo until the blastocyst stage during in-vitro fertilization (IVF) increased obstetric complications and twin births in a Nordic study. This finding is particularly important as there’s a spike in assisted reproduction technology (ART) treatments being performed with blastocyst transfer (BT) in recent years, according to the investigators.
A 3-day course of pivmecillinam to treat uncomplicated lower urinary tract infection (UTI) yielded similar outcomes as a 5-day course, suggesting that 3-day treatment may be sufficient, according to a study from Denmark.
Human papillomavirus (HPV) vaccination significantly reduces the frequency of genital HPV 16 and 18 infections and cervical intraepithelial neoplasia grade 2+ (CIN2+) in young women and shows signs of herd effects with a reduced frequency of anogenital warts in both young women and men, a recent study showed.
Patients undergoing assisted reproduction for non-male factor infertility do not derive greater benefit from intracytoplasmic sperm injection (ICSI) over in vitro fertilization (IVF), according to a study presented at ESHRE 2019.
Annual breast cancer screening with magnetic resonance imaging (MRI) led to detection of fewer late-stage and node-positive cancers than annual mammography, according to the FaMRIsc* study from the Netherlands. However, specificity was lower and number of false-positives higher with MRI vs mammography.
Children who were born after frozen embryo transfer (FET) showed comparable growth outcomes during their first 5 years of life as those who were born after fresh ET, according to a study presented at ESHRE 2019.
Treatment with the selective PARP* 1/2 inhibitor niraparib after a response to first-line platinum-based chemotherapy significantly extends progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, including those at high risk of relapse, according to the PRIMA** study presented at ESMO 2019.